The highway to a candidate antibody

An integrated platform for target/antibody validation



More info
R&D STEPS
All the expertise in one place

A unique environment for the development of immunotherapies in cancer and inflammation.

 

More info

Event

KEY ADVANCES ON IMMUNOTHERAPY AND CELLULAR THERAPY AGAINST CANCER AND INFLAMMATORY DISEASES

From  2019-03-28  to  2019-03-28 

MI-mAbs has partnered with Eurobiomed for this one-day symposium on immunotherapy antibodies and cellular therapies

See all events
The Highway from Start to Finish

The Highway from Start to Finish

Outsourcing R&D

PD1/CTLA4-based Combination Models

PD1/CTLA4-based Combination Models

Using syngeneic mouse models

mAb generation

mAb generation

Making the right Ab format

In Vitro Immunopharmacology

In Vitro Immunopharmacology

ADCC & ADCC-like assays

Antibody bioproduction

Antibody bioproduction

Milligram to gram scale production

CD3ɛ humanized mice

CD3ɛ humanized mice

First model to validate bispecifics

ADC's

ADC's

Site-specific conjugation

MI-mAbs

MI-mAbs

The French demonstrator of immunotherapy antibodies